Specific inhibition of the classical complement pathway prevents C3 deposition along the dermal-epidermal junction in bullous pemphigoid

Abstract Deposition of autoantibodies (α-BP180/230) and complement along the dermal-epidermal-junction is a hallmark of bullous pemphigoid (BP) and was shown to be important for pathogenesis. Given the adverse effects of standard treatment (glucocorticoids, immunosuppressants), there is an unmet need for safe and effective therapies. In this Phase 1 trial, we evaluated the safety and activity of BIVV009 (previously TNT009), a targeted C1s inhibitor, in 10 subjects with active or past BP (NCT02502903). Four weekly 60 mg/kg infusions of BIVV009 proved sufficient for inhibition of the classical complement pathway in all patients, as measured by CH50. C3c deposition along the dermal-epidermal-junction was partially or completely abrogated in 4/5 patients, where it was present at baseline. BIVV009 was found to be safe and tolerable in this elderly population, with only mild to moderate adverse events reported (e.g., headache, fatigue). One serious adverse event (i.e. fatal cardiac decompensation) occurred at the end of the post-treatment observation period in an 84-year-old patient with a history of diabetes and heart failure, but was deemed unlikely to be related to the study drug. This trial provides the first results with a complement-targeting therapy in BP, to our knowledge, and supports further studies on BIVV009's efficacy and safety in this population.